Abstract
Several single nucleotide polymorphisms (SNPs) within the CTLA-4 gene and elevated serum levels of soluble CTLA-4 (sCTLA-4) have been associated with autoimmunity including rheumatoid arthritis (RA). In this case–control study, we evaluated the relationship between the −319C/T (rs5742909) and CT60 G/A (rs3087243) SNPs and sCTLA-4 levels in 200 RA patients and 200 control subjects (CS) from Western Mexico. Both SNPs were genotyped with the polymerase chain reaction–restriction fragment length polymorphism technique and the sCTLA-4 levels were quantified using an enzyme-linked immunosorbent assay kit. In addition, we performed a haplotype analysis, including our previous data of the +49A/G (rs231775) SNP. The G/A genotype of the rs3087243 SNP was associated with a decreased risk of RA [odd ratio (OR) 0.61, 95 % confidence interval (CI) 0.38–0.96, p = 0.024]. This protection was also observed in the negative anti-cyclic citrullinated peptide group of RA carriers of the A allele (OR 0.48, 95 % CI 0.22–1.05, p = 0.042). On the contrary, we identified the −319C/+49G/CT60G haplotype of CTLA-4 gene as a risk factor for RA (OR 1.69, 95 % CI 1.13–2.52, p = 0.01). The sCTLA-4 levels were not associated with RA (p = 0.377), but were correlated with the functional disability of these patients (r = 0.282, p = 0.012). However, in CS the C/T genotype of the rs5742909 SNP, as well as the G/G and G/A genotypes of the rs3087243 SNP were associated with higher sCTLA-4 levels (p < 0.001). In conclusion, our results suggest that the −319C/+49G/CT60G haplotype of CTLA-4 gene is a genetic marker of susceptibility to RA in Western Mexico, whereas the rs3087243 SNP confers protection against this disease. Moreover, both SNPs showed an effect on the sCTLA-4 production in our control population. However, further studies are required to evaluate the role of sCTLA-4 in RA, as well as the molecular and functional basis of the association between both CTLA-4 gene SNPs and soluble levels of CTLA-4 in CS.
Similar content being viewed by others
References
Bax, M., van Heemst, J., Huizinga, T. W., & Toes, R. E. (2011). Genetics of rheumatoid arthritis: what have we learned? Immunogenetics, 63, 459–466.
Korhonen, R., & Moilanen, E. (2009). Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic & Clinical Pharmacology & Toxicology, 104, 276–284.
Andersson, A. K., Li, C., & Brennan, F. M. (2008). Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Research & Therapy, 10, 204–212.
Toh, M. L., & Miossec, P. (2007). The role of T cells in rheumatoid arthritis: new subsets and new targets. Current Opinion in Rheumatology, 19, 284–288.
Lundy, S. K., Sarkar, S., Tesmer, L. A., & Fox, D. A. (2007). Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research & Therapy, 9, 202–213.
Verhagen, J., Sabatos, C. A., & Wraith, D. C. (2008). The role of CTLA-4 in immune regulation. Immunology Letters, 115, 73–74.
Yokosuka, T., Kobayashi, W., Takamatsu, M., Sakata-Sogawa, K., Zeng, H., Hashimoto-Tane, A., et al. (2010). Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity, 33, 326–339.
Brand, O., Gough, S., & Heward, J. (2005). HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? Expert Reviews in Molecular Medicine, 7, 1–15.
Robert, C., & Ghiringhelli, F. (2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist, 14, 848–861.
Cutolo, M., Soldano, S., Montagna, P., Sulli, A., Seriolo, B., Villaggio, B., et al. (2009). CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Research & Therapy, 11, R176–R185.
Kristiansen, O. P., Larsen, Z. M., & Pociot, F. (2000). CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes and Immunity, 1, 170–184.
Magistrelli, G., Jeannin, P., Herbault, N., De Coignac, A. B., Gauchat, J. F., Bonnefoy, J. Y., et al. (1999). A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European Journal of Immunology, 29, 3596–3602.
Pawlak, E., Kochanowska, I. E., Frydecka, I., Kiełbiński, M., Potoczek, S., & Bilińska, M. (2005). The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis, 53, 336–341.
Oaks, M. K., Hallett, K. M., Penwell, R. T., Stauber, E. C., Warren, S. J., & Tector, A. J. (2000). A native soluble form of CTLA-4. Cellular Immunology, 201, 144–153.
Wang, X. B., Kakoulidou, M., Giscombe, R., Qiu, Q., Huang, D., Pirskanen, R., et al. (2002). Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. Journal of Neuroimmunology, 130, 224–232.
Liu, M. F., Wang, C. R., Chen, P. C., & Fung, L. L. (2003). Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scandinavian Journal of Immunology, 57, 568–572.
Sato, S., Fujimoto, M., Hasegawa, M., Komura, K., Yanaba, K., Hayakawa, I., et al. (2004). Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology, 43, 1261–1266.
Wong, C. K., Lit, L. C., Tam, L. S., Li, E. K., & Lam, C. W. (2005). Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology, 44, 989–994.
Luszczek, W., Kubicka, W., Jasek, M., Baran, E., Cisło, M., Nockowski, P., et al. (2006). CTLA-4 gene polymorphisms and natural soluble CTLA-4 protein in psoriasis vulgaris. International Journal of Immunogenetics, 33, 217–224.
Saverino, D., Brizzolara, R., Simone, R., Chiappori, A., Milintenda-Floriani, F., Pesce, G., et al. (2007). Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clinical Immunology, 123, 190–198.
Umemura, T., Ota, M., Hamano, H., Katsuyama, Y., Muraki, T., Arakura, N., et al. (2008). Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. American Journal of Gastroenterology, 103, 588–594.
Simone, R., Brizzolara, R., Chiappori, A., Milintenda-Floriani, F., Natale, C., Greco, L., et al. (2009). A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. International Immunology, 21, 1037–1045.
Momin, S., Flores, S., Angel, B. B., Codner, D. E., Carrasco, P. E., & Perez-Bravo, F. (2009). Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Research and Clinical Practice, 83, 289–294.
Toussirot, E., Saas, P., Deschamps, M., Pouthier, F., Perrot, L., Perruche, S., et al. (2009). Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Research & Therapy, 11, R101–R111.
Simmonds, M. J., & Gough, S. C. (2005). Genetic insights into disease mechanisms of autoimmunity. British Medical Bulletin, 71, 93–113.
Ueda, H., Howson, J. M., Esposito, L., Heward, J., Snook, H., Chamberlain, G., et al. (2003). Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature, 423, 506–511.
Fan, L. Y., Tu, X. Q., Cheng, Q. B., Zhu, Y., Feltens, R., Pfeiffer, T., et al. (2004). Cytotoxic T lymphocyte associated antigen-4 gene polymorphisms confer susceptibility to primary biliary cirrhosis and autoimmune hepatitis in Chinese population. World Journal of Gastroenterology, 10, 3056–3059.
Torres, B., Aguilar, F., Franco, E., Sánchez, E., Sánchez-Román, J., Alonso, J. J., et al. (2004). Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis and Rheumatism, 50, 2211–2215.
van Belzen, M. J., Mulder, C. J., Zhernakova, A., Pearson, P. L., Houwen, R. H., & Wijmenga, C. (2004). CTLA4 +49A/G and CT60 polymorphisms in Dutch coeliac disease patients. European Journal of Human Genetics, 12, 782–785.
Ban, Y., Tozaki, T., Taniyama, M., Tomita, M., & Ban, Y. (2005). Association of a CTLA-4 3′ untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity, 38, 151–153.
Zhang, Q., Yang, Y. M., & Lv, X. Y. (2006). Association of Graves’ disease and Graves’ ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. Journal of Zhejiang University Science B, 7, 887–891.
Mayans, S., Lackovic, K., Nyholm, C., Lindgren, P., Ruikka, K., Eliasson, M., et al. (2007). CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Medical Genetics, 8, 3–10.
Chang, M. C., Chang, Y. T., Tien, Y. W., Liang, P. C., Jan, I. S., Wei, S. C., et al. (2007). T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clinical Chemistry, 53, 1700–1705.
Kavvoura, F. K., Akamizu, T., Awata, T., Ban, Y., Chistiakov, D. A., Frydecka, I., et al. (2007). Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 92, 3162–3170.
Balbi, G., Ferrera, F., Rizzi, M., Piccioli, P., Morabito, A., Cardamone, L., et al. (2007). Association of −318 C/T and +49A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis. Clinical and Experimental Immunology, 149, 40–47.
Chong, K. K., Chiang, S. W., Wong, G. W., Tam, P. O., Ng, T. K., Hu, Y. J., et al. (2008). Association of CTLA-4 and IL-13 gene polymorphisms with Graves’ disease and ophthalmopathy in Chinese children. Investigative Ophthalmology & Visual Science, 49, 2409–2415.
Dallos, T., Avbelj, M., Barák, L., Zapletalová, J., Pribilincová, Z., Krajcírová, M., et al. (2008). CTLA-4 gene polymorphisms predispose to autoimmune endocrinopathies but not to celiac disease. Neuroendocrinology Letters, 29, 334–340.
Bicek, A., Zaletel, K., Gaberscek, S., Pirnat, E., Krhin, B., Stopar, T. G., et al. (2009). 49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Human Immunology, 70, 820–824.
Jin, P., Xiang, B., Lin, J., Huang, G., Zhou, W. D., Zheng, C., et al. (2009). Association of CTLA-4 +49A/G and CT60 gene polymorphism with type 1 diabetes and thyroid autoimmunity. Zhonghua Yi Xue Za Zhi, 89, 1246–1249.
Lei, C., Dongqing, Z., Yeqing, S., Oaks, M. K., Lishan, C., Jianzhong, J., et al. (2005). Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. European Journal of Human Genetics, 13, 823–828.
Plenge, R. M., Padyukov, L., Remmers, E. F., Purcell, S., Lee, A. T., Karlson, E. W., et al. (2005). Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. American Journal of Human Genetics, 77, 1044–1060.
Gonzalez-Escribano, M. F., Rodriguez, R., Valenzuela, A., Garcia, A., Garcia-Lozano, J. R., & Nuñez-Roldan, A. (1999). CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens, 53, 296–300.
Lee, Y. H., Choi, S. J., Ji, J. D., & Song, G. G. (2002). No association of polymorphisms of the CTLA-4 exon 1 (+49) and promoter (−318) genes with rheumatoid arthritis in the Korean population. Scandinavian Journal of Rheumatology, 31, 266–270.
Barton, A., Jury, F., Eyre, S., Bowes, J., Hinks, A., Ward, D., et al. (2004). Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis and Rheumatism, 50, 748–752.
Orozco, G., Torres, B., Núñez-Roldán, A., González-Escribano, M. F., & Martín, J. (2004). Cytotoxic T-lymphocyte antigen-4-CT60 polymorphism in rheumatoid arthritis. Tissue Antigens, 64, 667–670.
Zhernakova, A., Eerligh, P., Barrera, P., Wesoly, J. Z., Huizinga, T. W., Roep, B. O., et al. (2005). CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Human Genetics, 118, 58–66.
Suppiah, V., O’Doherty, C., Heggarty, S., Patterson, C. C., Rooney, M., & Vandenbroeck, K. (2006). The CTLA4 +49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Experimental and Molecular Pathology, 80, 141–146.
Torres-Carrillo, N., Torres-Carrillo, N. M., Vázquez-Del Mercado, M., Rangel-Villalobos, H., Parra-Rojas, I., Sánchez-Enríquez, S., et al. (2008). Distribution of -844 G/A and Hind III C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clinical and Applied Thrombosis/Hemostasis, 14, 220–226.
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism, 31, 315–324.
Cardiel, M. H., Abello-Banfi, M., Ruiz-Mercado, R., & Alarcon-Segovia, D. (1993). How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clinical and Experimental Rheumatology, 11, 117–121.
Leeb, B. F., Andel, I., Sautner, J., Bogdan, M., Maktari, A., Nothnagl, T., et al. (2005). Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis and Rheumatism, 53, 56–60.
Fleiss, J. L. (1981). Statistical methods for rates and proportions (2nd ed., pp. 38–45). New York: Wiley.
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16, 1215.
Excoffier, L., & Slatkin, M. (1995). Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Molecular Biology and Evolution, 12, 921–927.
Lewontin, R. C. (1964). The interaction of selection and linkage. I. General considerations; heterotic models. Genetics, 49, 49–67.
Gavrilets, S. (2001). Population genetics: multilocus. Encyclopedia of Life Sciences (pp. 1–5). Chichester: Wiley.
Lander, E., & Kruglyak, L. (1995). Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genetics, 11, 241–247.
Muñoz-Valle, J. F., Valle, Y., Padilla-Gutiérrez, J. R., Parra-Rojas, I., Rangel-Villalobos, H., del Mercado, M. V., et al. (2010). The +49A >G CTLA-4 polymorphism is associated with rheumatoid arthritis in Mexican population. Clinica Chimica Acta, 411, 725–728.
Szibor, R. (2007). X-chromosomal markers: past, present and future. Forensic Science International Genetics, 1, 93–99.
Wang, X. B., Zhao, X., Giscombe, R., & Lefvert, A. K. (2002). A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein. Genes and Immunity, 3, 233–234.
Ligers, A., Teleshova, N., Masterman, T., Huang, W. X., & Hillert, J. (2001). CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes and Immunity, 2, 145–152.
Kouki, T., Sawai, Y., Gardine, C. A., Fisfalen, M. E., Alegre, M. L., & DeGroot, L. J. (2000). CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. Journal of Immunology, 165, 6606–6611.
Han, S., Li, Y., Mao, Y., & Xie, Y. (2005). Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Human Genetics, 118, 123–132.
Ahmed, S., Ihara, K., Kanemitsu, S., Nakashima, H., Otsuka, T., Tsuzaka, K., et al. (2001). Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford), 40, 662–667.
Seidl, C., Donner, H., Fischer, B., Usadel, K. H., Seifried, E., Kaltwasser, J. P., et al. (1998). CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens, 51, 62–66.
Hadj Kacem, H., Bellassoued, M., Bougacha-Elleuch, N., Abid, M., & Ayadi, H. (2001). CTLA-4 gene polymorphisms in Tunisian patients with Graves’ disease. Clin Immunol, 101, 361–365.
Anjos, S., Nguyen, A., Ounissi-Benkalha, H., Tessier, M. C., & Polychronakos, C. (2002). A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. Journal of Biological Chemistry, 277, 46478–46486.
Daroszewski, J., Pawlak, E., Karabon, L., Frydecka, I., Jonkisz, A., Slowik, M., et al. (2009). Soluble CTLA-4 receptor an immunological marker of Graves’ disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. European Journal of Endocrinology, 161, 787–793.
Karabon, L., Kosmaczewska, A., Bilinska, M., Pawlak, E., Ciszak, L., Jedynak, A., et al. (2009). The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology, 128, e787–e796.
Wan, B., Nie, H., Liu, A., Feng, G., He, D., Xu, R., et al. (2006). Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol, 177, 8844–8850.
Purohit, S., Podolsky, R., Collins, C., Zheng, W., Schatz, D., Muir, A., et al. (2005). Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. Journal of Autoimmune Disease, 2, 8–13.
Cao, J., Zou, L., Luo, P., Chen, P., & Zhang, L. (2012). Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis. International Immunopharmacology, 14, 585–592.
Berry, A., Tector, M., & Oaks, M. K. (2008). Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. Journal of Negative Results in Biomedicine, 7, 8–11.
de Moor, C. H., Meijer, H., & Lissenden, S. (2005). Mechanisms of translational control by the 3′ UTR in development and differentiation. Seminars in Cell & Developmental Biology, 16, 49–58.
Torres-Carrillo, N., Torres-Carrillo, N. M., Martínez-Bonilla, G. E., Vázquez-Del Mercado, M., Palafox-Sánchez, C. A., Oregón-Romero, E., et al. (2009). Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. Clin Exp Med, 9, 223–228.
Acknowledgments
This study was supported by Grant No. 69235 to JFMV of the National Council of Science and Technology (CONACyT, México-Universidad de Guadalajara).
Conflict of Interest
None of the authors have any potential financial conflict of interest related to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Torres-Carrillo, N., Ontiveros-Mercado, H., Torres-Carrillo, N.M. et al. The −319C/+49G/CT60G Haplotype of CTLA-4 Gene Confers Susceptibility to Rheumatoid Arthritis in Mexican Population. Cell Biochem Biophys 67, 1217–1228 (2013). https://doi.org/10.1007/s12013-013-9640-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-013-9640-6